Skip to main content
IC
Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
755.57
+21.00 (2.86%)
At close: May 12, 2025, 4:00 PM
759.50
+3.93 (0.52%)
After-hours: May 12, 2025, 6:30 PM EDT

Eli Lilly Revenue by Segment
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
Diabetes
33.24B 29.52B 26.16B 23.47B 20.97B 19.67B 17.90B 16.84B
Diabetes Growth
58.49% 50.10% 46.17% 39.40% 37.36% 35.97% 26.78% 22.67%
Oncology
8.89B 8.75B 8.08B 7.60B 7.11B 6.66B 6.43B 5.97B
Oncology Growth
24.99% 31.45% 25.83% 27.27% 25.46% 17.51% 18.46% 7.85%
Immunology
4.65B 4.39B 4.21B 4.01B 3.85B 3.80B 3.63B 3.51B
Immunology Growth
20.59% 15.68% 15.98% 14.30% 14.21% 13.54% 7.70% 0.01%
Neuroscience
1.36B 1.47B 1.44B 2.86B 2.91B 2.88B 2.90B 1.51B
Neuroscience Growth
-53.34% -48.81% -50.26% 89.84% 92.66% 86.18% 77.83% -11.84%
Other
873.90M 902.90M 968.50M 981.80M 1.09B 1.12B 1.22B 1.69B
Other Growth
-19.74% -19.54% -20.74% -41.97% -41.83% -68.12% -74.00% -63.16%

Revenue by Geography
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
US
33.17B 30.38B 27.80B 25.35B 23.05B 21.79B 19.99B 19.05B
US Growth
43.91% 39.39% 39.03% 33.10% 32.07% 19.80% 6.88% 4.23%
Europe
7.87B 6.92B 5.81B 6.75B 6.52B 6.17B 5.91B 4.40B
Europe Growth
20.61% 12.08% -1.71% 53.44% 50.93% 43.62% 35.21% -0.34%
Rest of World
4.38B 4.27B 3.95B 3.62B 3.17B 2.95B 3.02B 2.88B
Rest of World Growth
38.20% 44.97% 30.64% 25.97% 14.14% 3.30% 8.23% 0.86%
Japan
1.85B 1.81B 1.69B 1.66B 1.65B 1.67B 1.63B 1.73B
Japan Growth
12.34% 8.50% 4.06% -4.00% -4.35% -4.28% -13.70% -13.48%
China
1.74B 1.66B 1.61B 1.54B 1.54B 1.54B 1.51B 1.47B
China Growth
12.43% 7.83% 6.28% 5.01% 8.75% 5.98% 2.35% -4.53%

Operating Expense Breakdown
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
Research and Development
11.20B 10.99B 10.53B 10.21B 9.85B 9.31B 8.75B 8.14B
Research and Development Growth
13.71% 18.01% 20.40% 25.37% 30.21% 29.52% 22.26% 15.30%
Marketing, Selling, and Administrative
9.11B 8.59B 8.09B 7.80B 7.61B 7.40B 7.12B 6.93B
Marketing, Selling, and Administrative Growth
19.78% 16.08% 13.65% 12.49% 14.69% 14.95% 11.46% 9.12%
Acquired In-Process Research and Development
4.74B 3.28B 3.71B 3.86B 3.81B 3.80B 3.42B 504.60M
Acquired In-Process Research and Development Growth
24.61% -13.67% 8.68% 665.46% 348.79% 318.25% 208.95% -58.68%
Impairment, Restructuring, and Other
895.60M 860.60M 523.37M 441.77M - 6.77M - -
Impairment, Restructuring, and Other Growth
- 12,611.96% - - - -97.23% - -
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.